GeneOne Life Science Announces Paid-in Capital Increase
진원생명과학
011000
Signal Score
Historical Avg Return (5d)
+0.00%
Data Coverage
100%n=2692
Risk-adjusted indicator based on 2692 historical DART filings. For informational purposes only — not investment advice.
Financial Impact
NEGATIVE
Key Numbers
- • New Share Issuance Price: 2,410 KRW per share
- • Reference Share Price (pre-discount): 2,670 KRW
- • Discount Rate: 10%
- • Previous Trading Halt Closing Price (June 24, 2026): 534 KRW
- • Expected New Major Shareholder: Revolt Investment Association (25.51% ownership)
AI Analysis Summary
GeneOne Life Science has decided on a paid-in capital increase via third-party allocation. The new shares will be issued at 2,410 KRW per share, a 10% discount from the reference price of 2,670 KRW. This reference price is 5 times the pre-trading halt closing price of 534 KRW on June 24, 2026, following a 5:1 stock consolidation. The capital increase is expected to change the largest shareholder from Dongban Growth Investment Association No. 1 (8.49%) to Revolt Investment Association (25.51%), with a 1-year lock-up period. The specific use of funds is not detailed, and the new major shareholder, Revolt Investment Association, was established recently on July 29, 2026, lacking prior financial statements. This dilution event, coupled with a significant change in major shareholder and lack of detailed fund usage, presents a negative outlook for existing shareholders.
How This Event Is Evaluated
Capital Raise Evaluation
Capital raise events are evaluated by estimating dilution pressure, funding purpose, pricing terms, and impact on existing shareholders.
AI is used to interpret disclosures and extract structured data.
Signal scores are generated using event-specific methodologies and quantitative models.
- Potential dilution rate
- Issuance or conversion price
- Funding purpose
- Shareholder value impact
This content is for informational purposes only and does not constitute investment advice. Past signal patterns do not guarantee future results. All data is sourced from public DART filings.